Prof. Massimo Lazzeri (IT) elaborates on the trial he presented at ASCO GU23: Randomized phase III clinical trial of neoadjuvant intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve non-muscle invasive bladder cancer (NMIBC).
